In tumor progression, co-inhibitory checkpoint molecules are actively exploited to evade immunosurveillance (10), and a co-inhibitory immune checkpoint molecule blockade was confirmed to enhance the antitumor activity and maintain the highly durable antitumor immune responses of CD8+ TILs (11). This evidence concerns the gene CD8A and neoplasm.